Intravenous immunoglobulin therapy for Miller Fisher syndrome.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 17404197.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.
Medical subject headings
- Immunoglobulins, Intravenous
- Miller Fisher Syndrome